A Phase 2 interventional study of Cytisine and Placebo Comparator in Smoking Cessation, sponsored by Achieve Life Sciences. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-18.
Sponsored by Achieve Life Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.
Among the 22 studies testing cytisine in Smoking Cessation, this one is the 11th largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 7th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health
Ages 18+
Maimónides Biomedical Research Institute of Córdoba
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 7 · Phase 4 3
First in 2016; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 254 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 202 across the 22 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
Achieve Life Sciences is the lead sponsor of 31 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 8 (67%) have results posted.
10 studies in Smoking Cessation by Achieve Life Sciences: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Smoking Cessation by Achieve Life Sciences, this one is the 4th largest by enrollment, is one of 2 that started in 2018, is the only one in phase 2, and was the 4th registered.
Achieve Life Sciences’s Smoking Cessation studies by the year they started, since 2017.
1 of the studies testing cytisine in Smoking Cessation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06617312University of California, Los AngelesExamining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing cytisine in Smoking Cessation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Achieve Life Sciences’s 10 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This placebo-controlled Phase 2b trial is being conducted at sites within the United States (US) to evaluate the effectiveness cytisine dosage (1.5 mg, 3.0 mg) and administration schedule (commercial titration versus simplified 3 times daily [TID] schedule) within a 25-day treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
Drug: Cytisine · Behavioral: Behavioral support
3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
Drug: Cytisine · Behavioral: Behavioral support
Placebo tablets using the commercial 25-day titration schedule + behavioral support
Drug: Placebo Comparator · Behavioral: Behavioral support
1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support
Drug: Cytisine · Behavioral: Behavioral support
3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support
Drug: Cytisine · Behavioral: Behavioral support
Placebo tablets for 25 days using a simplified TID schedule + behavioral support
Drug: Placebo Comparator · Behavioral: Behavioral support
film coated tablet containing 1.5 mg cytisine in a single tablet
1.5 mg cellulose powder to match final weight of the cytisine tablet
12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
Primary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment
The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. The percentage of expected cigarettes smoked was computed as Y = (100 x N) / (T x R) where N represents total number of cigarettes smoked each day over the treatment period from Day 1 to Day 25; T represents number of post-randomization days where number of cigarettes smoked is recorded; and R represents the average number of cigarettes smoked daily over the 7-day screening period as baseline. T\*R represents the total number of cigarettes that would have been smoked without intervention over the number of recorded days. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).
Time frame: Day 1 through Day 25
Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, Commercial Schedule
The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of "Statistical Analysis 5" for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).
Time frame: Day 1 through Day 25
Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, TID Schedule
The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of "Statistical Analysis 5" for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).
Time frame: Day 1 through Day 25
| Milestone | 1.5 mg Cytisine, Commercial Schedule | 3.0 mg Cytisine, Commercial Schedule | Placebo, Commercial Schedule | 1.5 mg Cytisine, TID Schedule | 3.0 mg Cytisine, TID Schedule | Placebo, TID Schedule |
|---|---|---|---|---|---|---|
| Started | 51 | 50 | 25 | 52 | 50 | 26 |
| Completed | 48 | 45 | 22 | 50 | 49 | 26 |
| Not completed | 3 | 5 | 3 | 2 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 | 2 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 0 | 0 | 0 | 1 | 0 | 0 |
The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. The percentage of expected cigarettes smoked was computed as Y = (100 x N) / (T x R) where N represents total number of cigarettes smoked each day over the treatment period from Day 1 to Day 25; T represents number of post-randomization days where number of cigarettes smoked is recorded; and R represents the average number of cigarettes smoked daily over the 7-day screening period as baseline. T\*R represents the total number of cigarettes that would have been smoked without intervention over the number of recorded days. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).
| percentage of cigarettes smoked | 1.5 mg Cytisine, Commercial Schedule | 3.0 mg Cytisine, Commercial Schedule | Placebo, Commercial Schedule | 1.5 mg Cytisine, TID Schedule | 3.0 mg Cytisine, TID Schedule | Placebo, TID Schedule |
|---|---|---|---|---|---|---|
| Primary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment | 26.62 ± 3.085 | 25.04 ± 3.123 | 47.10 ± 4.417 | 29.40 ± 3.046 | 32.50 ± 3.105 | 35.30 ± 4.392 |
The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of "Statistical Analysis 5" for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).
| percentage of expected cigarettes smoked | 1.5 mg Cytisine, Commercial Schedule | 3.0 mg Cytisine, Commercial Schedule | Pooled Placebo |
|---|---|---|---|
| Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, Commercial Schedule | 26.68 ± 3.065 | 25.08 ± 3.100 | 41.29 ± 3.099 |
The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of "Statistical Analysis 5" for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).
| percentage of expected cigarettes smoked | 1.5 mg Cytisine, TID Schedule | 3.0 mg Cytisine, TID Schedule | Pooled Placebo |
|---|---|---|---|
| Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, TID Schedule | 29.29 ± 3.291 | 32.41 ± 3.355 | 41.71 ± 3.358 |
Collected over From 1st dose of study drug through Week 8 (± 3 days) post-randomization. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.5 mg Cytisine, Commercial Schedule | 0/51 (0%) | 0/51 (0%) | 16/51 (31.4%) |
| 3.0 mg Cytisine, Commercial Schedule | 0/50 (0%) | 0/50 (0%) | 16/50 (32%) |
| Placebo, Commercial Schedule | 0/25 (0%) | 0/25 (0%) | 5/25 (20%) |
| 1.5 mg Cytisine, TID Schedule | 0/52 (0%) | 0/52 (0%) | 15/52 (28.8%) |
| 3.0 mg Cytisine, TID Schedule | 0/50 (0%) | 0/50 (0%) | 14/50 (28%) |
| Placebo, TID Schedule | 0/26 (0%) | 0/26 (0%) | 8/26 (30.8%) |
| Event | 1.5 mg Cytisine, Commercial Schedule | 3.0 mg Cytisine, Commercial Schedule | Placebo, Commercial Schedule | 1.5 mg Cytisine, TID Schedule | 3.0 mg Cytisine, TID Schedule | Placebo, TID Schedule |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/51 | 3/50 | 1/25 | 1/52 | 3/50 | 4/26 |
| Upper respiratory tract infectionInfections and infestations | 3/51 | 2/50 | 3/25 | 5/52 | 3/50 | 4/26 |
| Abnormal dreamsPsychiatric disorders | 4/51 | 7/50 | 1/25 | 4/52 | 3/50 | 0/26 |
| HeadacheNervous system disorders | 1/51 | 1/50 | 0/25 | 6/52 | 2/50 | 2/26 |
| AnxietyPsychiatric disorders | 1/51 | 1/50 | 0/25 | 0/52 | 1/50 | 3/26 |
| InsomniaPsychiatric disorders | 3/51 | 4/50 | 1/25 | 4/52 | 3/50 | 0/26 |
| GastroenteritisInfections and infestations | 1/51 | 0/50 | 0/25 | 2/52 | 1/50 | 2/26 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/51 | 0/50 | 0/25 | 0/52 | 0/50 | 2/26 |
| ConstipationGastrointestinal disorders | 0/51 | 0/50 | 0/25 | 1/52 | 3/50 | 1/26 |
| FatigueGeneral disorders | 1/51 | 2/50 | 1/25 | 3/52 | 1/50 | 1/26 |
| Age, Continuous(years) | 1.5 mg Cytisine, Commercial Schedule | 3.0 mg Cytisine, Commercial Schedule | Placebo, Commercial Schedule | 1.5 mg Cytisine, TID Schedule | 3.0 mg Cytisine, TID Schedule | Placebo, TID Schedule | Total |
|---|---|---|---|---|---|---|---|
| Mean | 49.8 ± 11.46 | 50.0 ± 13.20 | 51.0 ± 15.16 | 47.0 ± 13.67 | 46.3 ± 12.88 | 47.0 ± 12.64 | 48.4 ± 13.04 |
| Sex: Female, Male(Participants) | 1.5 mg Cytisine, Commercial Schedule | 3.0 mg Cytisine, Commercial Schedule | Placebo, Commercial Schedule | 1.5 mg Cytisine, TID Schedule | 3.0 mg Cytisine, TID Schedule | Placebo, TID Schedule | Total |
|---|---|---|---|---|---|---|---|
| Female | 28 | 20 | 14 | 29 | 25 | 17 | 133 |
| Male | 23 | 30 | 11 | 23 | 25 | 9 | 121 |
| Race (NIH/OMB)(Participants) | 1.5 mg Cytisine, Commercial Schedule | 3.0 mg Cytisine, Commercial Schedule | Placebo, Commercial Schedule | 1.5 mg Cytisine, TID Schedule | 3.0 mg Cytisine, TID Schedule | Placebo, TID Schedule | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Asian | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 9 | 3 | 13 | 7 | 7 | 46 |
| White | 43 | 40 | 21 | 37 | 41 | 18 | 200 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 0 | 1 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | 1.5 mg Cytisine, Commercial Schedule | 3.0 mg Cytisine, Commercial Schedule | Placebo, Commercial Schedule | 1.5 mg Cytisine, TID Schedule | 3.0 mg Cytisine, TID Schedule | Placebo, TID Schedule | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 2 | 6 | 1 | 0 | 15 |
| Not Hispanic or Latino | 45 | 49 | 23 | 46 | 49 | 26 | 238 |
| Native American | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Average Number of Cigarettes Smoked per Day Over 7 Consecutive Days(cigarettes per day) | 1.5 mg Cytisine, Commercial Schedule | 3.0 mg Cytisine, Commercial Schedule | Placebo, Commercial Schedule | 1.5 mg Cytisine, TID Schedule | 3.0 mg Cytisine, TID Schedule | Placebo, TID Schedule | Total |
|---|---|---|---|---|---|---|---|
| Mean | 17.6 ± 5.30 | 18.0 ± 5.51 | 16.7 ± 4.28 | 18.0 ± 6.69 | 18.0 ± 6.12 | 18.0 ± 5.96 | 17.8 ± 5.75 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2018 to primary completion in Apr 2019, 5 months.
Results were first posted in May 2020, 1 year after primary completion.
Of 51 phase 2 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cytisine